Aspiration pneumonia bacterial infection medical therapy: Difference between revisions
m (Robot: Automated text replacement (-msbeih@perfuse.org +msbeih@wikidoc.org, -psingh@perfuse.org +psingh13579@gmail.com, -agovi@perfuse.org +agovi@wikidoc.org, -rgudetti@perfuse.org +ravitheja.g@gmail.com, -lbiller@perfuse.org +lbiller@wikidoc.org,...) |
Ochuko Ajari (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Aspiration pneumonia bacterial infection}} | {{Aspiration pneumonia bacterial infection}} | ||
{{CMG}}; {{AE}} [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com] | |||
===Medical therapy=== | ===Medical therapy=== | ||
====Antibiotics==== | ====Antibiotics==== | ||
Line 13: | Line 14: | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Diseaase]] | [[Category:Diseaase]] | ||
Line 20: | Line 21: | ||
[[Category:Pneumonia|Pneumonia]] | [[Category:Pneumonia|Pneumonia]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Needs overview]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 20:49, 4 March 2013
Aspiration pneumonia bacterial infection Microchapters |
Differentiating Aspiration pneumonia bacterial infection from other Diseases |
---|
Diagnosis |
Treatment |
Aspiration pneumonia bacterial infection medical therapy On the Web |
American Roentgen Ray Society Images of Aspiration pneumonia bacterial infection medical therapy |
FDA on Aspiration pneumonia bacterial infection medical therapy |
CDC onAspiration pneumonia bacterial infection medical therapy |
Aspiration pneumonia bacterial infection medical therapy in the news |
Blogs on Aspiration pneumonia bacterial infection medical therapy |
Directions to Hospitals Treating Aspiration pneumonia bacterial infection |
Risk calculators and risk factors for Aspiration pneumonia bacterial infection medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.D. [2]
Medical therapy
Antibiotics
- Treatment of choice clindamycin
- Doses 600 mg Q8hourly, followed by 300 mg Q6hourly, or 450 mg tid
- Advantage of clindamycin :
- Cheap
- Less incidences of superimposed MRSA
- Other agents used: Ampicillin-sulbactam (1.5 g or 3 g twice daily), Imipenem (Invanz 500 mg BID), amoxicillin-clavulnate (875 mg orally bid), penicillin (1 to 2 million units IV Q6hourly) / amoxicillin (500 mg orally tid)+ metronidazole (500 mg orally or IV tid).
- Monotherapy with metronidazole is not preferred as high failure rates have been reported. This is because metronidazole is ineffective against some pathogens such as microaerophilic and aerobic streptococci